24 results on '"Vermij, Lisa"'
Search Results
2. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
3. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
4. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
5. Clinical Behavior and Molecular Landscape of Stage I p53-abnormal Low-Grade Endometrioid Endometrial Carcinomas
6. QPOLE: A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction
7. QPOLE:A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction
8. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
9. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
10. EP116/#725 Low-grade p53abn endometrial carcinomas exist and are associated with a high risk of recurrence, even in low-stage disease
11. 2022-RA-925-ESGO Development of adjuvant treatment decision support tool for endometrial cancer patients by pooled analysis of data from 2000 women included in the PORTEC-1–3 trials and a prospective cohort study
12. 2022-RA-568-ESGO Prognostic Relevance of FIGO grading is Limited to NSMP Endometrial Cancers
13. p53 immunohistochemistry in endometrial cancer:clinical and molecular correlates in the PORTEC-3 trial
14. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients - a TransPORTEC study
15. Performance of a HER2 testing algorithm specific for p53‐abnormal endometrial cancer
16. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer
17. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer
18. HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes
19. Incorporation of molecular characteristics into endometrial cancer management
20. Incorporation of molecular characteristics into endometrial cancer management.
21. ABO incompatibility and RhIG immunoprophylaxis protect against non‐D alloimmunization by pregnancy
22. HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes.
23. Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low.
24. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.